Mycophenolate mofetil monotherapy in the management of paediatric uveitis

Chang, Peter Y.; Giuliari, Gian Paolo; Shaikh, Mehrine; Thakuria, P.; Makhoul, Dorine; Foster, C. Stephen

doi:10.1038/eye.2011.23

Cited by 51 publications

(25 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…During MPS treatment, a significant reduction of the uveitis reactivation rate was observed. In the literature, favourable treatment results have been previously reported in children with uveitis treated with MMF 5 7 8. Obviously, MPS has similar immunosuppressive potency as MMF in the therapy of uveitis in childhood.…”

Section: Discussionmentioning

confidence: 97%

“…The derivative of MPA, mycophenolate mofetil (MMF), has been shown to be an effective immunosuppressive agent in the treatment of non-infectious uveitis 2–6. MMF has been also reported to be a promising agent in the therapy of children with uveitis 5 7 8. Although MMF is a well-tolerated drug, gastrointestinal discomfort is the most common side effect and the necessity of dose reduction, interruption or even therapy discontinuation may limit the clinical benefit 9.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Mycophenolate sodium for the treatment of chronic non-infectious uveitis of childhood

et al. 2015

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 97%

Section: Introductionmentioning

confidence: 99%

Mycophenolate sodium for the treatment of chronic non-infectious uveitis of childhood

et al. 2015

View full text Add to dashboard Cite

show abstract

“…However, the treatment had to be stopped due to side effects in 6 patients (11.5%), specially gastrointestinal disturbances. 61 No randomized controlled trials have been performed in this area. It should be noted that Mycophenolate mofetil is not routinely used in patients with severe joint disease because it is not considered to be effective in treating arthritis.…”

Section: Mycophenolate Mofetilmentioning

confidence: 99%

Managing juvenile idiopathic arthritis–associated uveitis

Hawkins

Dick

Lee

et al. 2016

Survey of Ophthalmology

View full text Add to dashboard Cite

show abstract

“…45 Being used alone or in combination with other steroid-sparing immunosuppressive drugs, MMF has been reported to be effective for uveitis in both children 97,101 and adults, at different locations of the uvea (anterior, intermediate, posterior/panuveitis), 44,[104][105] as well as specific entities including sarcoidosis 99 and VKH. 103 In the Systemic Immunosuppressive Therapy for Eye Diseases (SITE) Cohort Study, the efficacy and safety profiles of MMF as the single initial corticosteroid sparing immunosuppressive agent were unremarkable with reference to alternative immunosuppressive drugs used in this same cohort, but a good long-term tolerance rate as with MTX, was observed.…”

Section: Mmfmentioning

confidence: 99%

“…42 Despite its limited experiences in practice of uveitis, this drug has gained considerable popularity, reflected by the emerging publications on its effectiveness in this particular field, 44,[97][98][99][100][101][102][103] as well as its second priority among uveitis specialists' current choices of immunosuppressive drugs in the United…”

Section: Mmfmentioning

confidence: 99%

Immunosuppressive Treatment of Non-infectious Uveitis: History and Current Choices

Zhao¹,

Zhang²

2017

cmsj

View full text Add to dashboard Cite

Non-infectious uveitis is one of the leading causes of preventable blindness worldwide. Long-term immunosuppressive treatment is generally required to achieve durable control of inflammation in posterior and panuveitis. Although systemic corticosteroids have been the gold standard of immunosuppressive treatment for uveitis since first introduced in 1950s, its side effects of long-term use often warrant an adjuvant treatment to reduce the dosage/duration of corticosteroids needed to maintain disease control. Conventional immunosuppressive drugs, classified into alkylating agent, antimetabolites and T cell inhibitors, have been widely used as corticosteroid-sparing agents, each with characteristic safety/tolerance profiles on different uveitis entities. Recently, biologic agents, which target specific molecules in immunopathogenesis of uveitis, have gained great interest as alternative treatments for refractory uveitis based on their favorable safety and effectiveness in a variety of uveitis entities. However, lack of large randomized controlled clinical trials, concerns about efficacy and safety of long-term usage, and economic burden are limiting the use of biologics in non-infectious uveitis. Local administration of immunosuppressive drugs (from corticosteroids to biologics) through intraocular drug delivery systems represent another direction for drug development and is now under intense investigation, but more evidences are needed to support their use as regular alternative treatments for uveitis. With the numerous choices belonging to different treatment modalities (conventional immunosuppressive agents, biologics and local drug delivery systems) on hand, the practice patterns have been reported to vary greatly from center to center. Factors influence uveitis specialists' choices of immunosuppressive agents may be complex and may include personal familiarity, treatment availability, safety/tolerability, effectiveness, patient compliance, cost concerns and suggestions from related specialists such as rheumatologists and pediatricians. The focus of this review is to provide an overview of each treatment modality on safety/tolerability and effectiveness, which are believed to be the two most important factors affecting treatment decision making.

show abstract

Mycophenolate mofetil monotherapy in the management of paediatric uveitis

Cited by 51 publications

References 30 publications

Mycophenolate sodium for the treatment of chronic non-infectious uveitis of childhood

Mycophenolate sodium for the treatment of chronic non-infectious uveitis of childhood

Managing juvenile idiopathic arthritis–associated uveitis

Immunosuppressive Treatment of Non-infectious Uveitis: History and Current Choices

Contact Info

Product

Resources

About